Although the mechanistic basis for this relationship remains unknown, variation in tumor 24-hydroxylase levels may contribute to a differential benefit of vitamin D supplementation in patients with KRAS-mutant and EGFR-mutant tumors. The gene discussed is KRAS; the disease is neoplasm.